Medicines Safety Update No.1; 2010
This issue of Medicines Safety Update was published in the February 2010 issue of Australian Prescriber.
Medicines Safety Update, a new publication from the Therapeutic Goods Administration (TGA), will appear in each edition of Australian Prescriber. Medicines Safety Update is replacing the Australian Adverse Drug Reactions Bulletin and will bring you practical information and advice on drug safety as well as keeping you informed about emerging safety issues.
In this edition:
- the Advisory Committee on the Safety of Medicines (ACSOM) - this is the TGA's new expert advisory committee on medicines safety and replaces the Adverse Drug Reactions Advisory Committee (ADRAC)
- Medicines Risk Management Plans - what are they and how are they used?
- development of a new medicines alert system to replace the ADRAC Drugs of Current Interest Scheme
- regular articles about emerging safety issues
The TGA, Australia's national regulator of therapeutic products, is responsible for ensuring that medicines, medical devices, blood, tissues and cellular therapies meet appropriate standards of safety, quality and efficacy and are made available to the community in a timely manner.
In keeping with international initiatives, the TGA is implementing some important changes to the way in which it monitors and manages the safety of medicines and communicates important benefit-risk information about medicines to its stakeholders.
In April 2009 the TGA formally adopted the European Guideline on Risk Management Systems for Medicinal Products for Human Use (EMEA/CHMP/96268/2005).
Adoption of this guideline means that applications for the registration of certain higher risk prescription medicines (new chemical entities, applications for paediatric use, new dosage forms, new routes of administration and significant extensions of indication) are now required to include a Risk Management Plan as part of the application.
The Risk Management Plan is meant to document not only what is known about the safety of the medicine at that particular point in time (termed the Safety Specifications), but also potential risks that require further elucidation, and how the sponsor intends to investigate those risks. The sponsor is required to establish a plan for monitoring the medicine when it is approved (a so-called Pharmacovigilance Plan) and consider whether there is a need for additional risk minimisation activities (such as additional prescribing and educational material, restrictions on promotion of and access to the medicine) and outline these in a Risk Minimisation Plan.
A new expert advisory committee on medicines safety, called the Advisory Committee on the Safety of Medicines (ACSOM), has replaced ADRAC. This new committee exists as a statutory committee in its own right and has broader and enhanced terms of reference compared to ADRAC. A key role of the ACSOM will be the provision of expert advice to the TGA about the appropriateness of risk management plans and risk minimisation strategies for new high-risk medicines.
The TGA is also committed to enhancing its dissemination of important benefit - risk information for medicines.
Legislation amendments enacted in 2009 have expanded the range of regulatory information the TGA may release, while protecting commercially sensitive and personal information. This will allow the TGA to publish on its website recommendations from external advisory committees and summary decision statements on evaluations of prescription medicines.
Over the next 12 months, the TGA will be progressively publishing a variety of documents on its website:
- Product information (PI) - this document contains a concise scientific summary of what is known about a medicine, targeted at healthcare professionals
- Consumer Medicines Information (CMI) - this document presents information about the use and safety of a medicine in lay language
- Australian Product Assessment Report (AUSPAR) - this document contains detailed technical and scientific assessments of the efficacy, safety and benefit - risk of the medicine undertaken by the TGA and the considerations that led the TGA to approve or reject an application. An AUSPAR will be prepared for submissions that relate to new chemical entities, generic medicines, major variations, and extension of indications.
When this project is completed, the TGA website will provide a single point at which healthcare professionals, consumers and other interested parties can locate current, authoritative and reliable information about a medicine that is registered on the Australian Register of Therapeutic Goods (ARTG).
Check out regular updates of suspected adverse reactions to the vaccine at: Pandemic (H1N1) 2009 Influenza vaccine - alerts & advisories
The cornerstone of medicines safety monitoring is spontaneous adverse event and incident reporting, so it's important that you continue to report adverse reactions to the TGA's Office of Medicines Safety Monitoring (OMSM).
The Blue Card system has been in operation for more than three decades and has resulted in more than 200 000 adverse drug reaction reports.
Anyone can report a suspected adverse drug reaction and the OMSM receives approximately 12 000 reports per year.
The Blue Card reporting form will continue to be distributed with the April, August and December issues of Australian Prescriber.
The TGA encourages the reporting of all suspected adverse reactions to medicines, including vaccines, over-the-counter medicines, herbal, traditional or alternative remedies. The TGA particularly requests reports of:
- ALL suspected reactions to new medicines
- ALL suspected medicines interactions
- Suspected reactions causing
- admission to hospital or prolongation of hospitalisation
- increased investigations or treatments
- birth defects
For blue cards
Reports of suspected adverse drug reactions are best made by using a prepaid reporting form ('blue card') which is available from the website: Report of suspected adverse reaction to medicines/vaccines or from the Office of Product Review, phone 1800 044 114.
Reports can also be submitted:
- online - on the TGA website and click on 'Report a problem' on the right
- fax 02 6232 8392
- email ADR.Reports@tga.gov.au
For further information from the Office of Product Review:
- Phone: 1800 044 114
- Fax: 02 6232 8392
- Email: ADR.Reports@tga.gov.au
© Commonwealth of Australia 2010
This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to <email@example.com>.